The latest update is out from Kamada ( (IL:KMDA) ).
Kamada Ltd. announced it will release its financial results for the fourth quarter and fiscal year 2024 on March 5, 2025. The company will host a conference call to discuss these results, reflecting its ongoing commitment to transparency and engagement with stakeholders. This announcement is part of Kamada’s broader strategy to drive growth through product commercialization, business development, and expansion of plasma collection operations.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company focuses on treating rare and serious conditions and has a portfolio that includes FDA-approved products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®. Kamada is expanding its operations through organic growth, business development, and plasma collection, with plans to open a new plasma collection center in San Antonio, Texas.
YTD Price Performance: 14.22%
Average Trading Volume: 184,112
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $416.6M
See more insights into KMDA stock on TipRanks’ Stock Analysis page.